Barclays Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott maintains an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) and lowers the price target from $14 to $9.
September 29, 2023 | 10:08 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Pacific Biosciences but lowered the price target from $14 to $9.
The lowering of the price target by Barclays from $14 to $9 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Pacific Biosciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100